期刊文献+

恶性肿瘤患者并发静脉血栓栓塞的临床研究 被引量:8

Clinical studies in patients with cancer complicated by venous thromboembolism
原文传递
导出
摘要 目的:探讨恶性肿瘤患者血栓治疗的意义。方法:观察370例恶性肿瘤患者的静脉血栓发生率,检测所有患者的凝血功能和D-二聚体。血栓组18例患者给予低分子肝素钠5 000 U皮下注射(1次/12 h,共2次)以及常规抗肿瘤治疗。分析血栓形成的危险因素。比较血栓组和非血栓组患者的总生存和无进展生存的差异。结果:370例恶性肿瘤患者的血栓发生率为4.9%。血栓组的活化部分凝血活酶时间和凝血酶时间较非血栓组缩短(P<0.01),凝血酶原时间延长(P<0.01),纤维蛋白原升高(P<0.01),血栓组的D-二聚体高于非血栓组(P<0.05)。血栓组与非血栓组患者的总生存差异无统计学意义(P=0.690);非血栓组患者的中位无进展生存期较血栓组患者明显延长(P=0.002)。置入静脉导管(P=0.004)和升高白细胞治疗(P=0.035)是影响血栓形成的独立因素。结论:恶性肿瘤并发血栓患者可从抗凝治疗联合抗肿瘤治疗中获益。升高白细胞治疗和置入静脉导管是血栓形成的独立危险因素。 Objective: To investigate the clinical significance of treatment of thrombosis in patients with malignant tumors. Methods: The incidence rate of venous thromboembolism (VTE) in 370 patients with malignant tumors was calculated. The coagulant function and D-dimer of all patients were examined. Eighteen patients with VTE received low molecular heparin sodium (subcutaneous injection of 5 000 U low molecular heparin sodium every 12 h for 2 times) and conventional anti-tumor therapy. The risk factors related to VTE were analyzed. The overall survival (OS) and progression-free survival (PFS) were compared between VTE group and non-VTE group. Results: In 370 patients with malignant tumors, the incidence rate of VTE was 4.9%. The activated partial thromboplastin time (APTT) and thrombin time (-I-1-) were shortened in VTE group as compared with those in non-VTE group (P 〈 0.01). The prothrombin time (PT) was prolonged and the level of fibrinogen (FIB) was increased in VTE group (P 〈 0.01). The level of D-dimer was higher in VTE group than that in non-VTE group (P 〈 0.05). The OS between VTE group and non-VTE group was not significantly different (P = 0.690). The median PFS of non-VTE group was significantly prolonged as compared with that of VTE group (P = 0.002). Venous catheter placement (P = 0.004) and therapy of elevating white blood cell count (P = 0.035) were independent risk factors affecting VTE. Conclusion: Malignant tumor patients with VTE can benefit from anticoagulation and anti-tumor treatment. Venous catheter placement and therapy of elevating white blood cell count are the independent risk factors affecting VTE.
出处 《肿瘤》 CAS CSCD 北大核心 2014年第8期745-749,共5页 Tumor
基金 河北省卫生厅青年科技课题资助项目(编号:20110459)
关键词 恶性肿瘤 静脉血栓栓塞 预后 治疗 Malignant neoplasms Venous thromboembolism Prognosis Treatment
  • 相关文献

参考文献16

二级参考文献56

共引文献513

同被引文献52

引证文献8

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部